Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 3, 2003, Pages 963-968

  Ben Shlomo, Anat ^a   Melmed, Shlomo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; LONG ACTING DRUG; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CANCER SURGERY; DRUG EFFECT; HUMAN; LUNG FUNCTION TEST; PATIENT CARE; PERIOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REMISSION; REVIEW; SLOW RELEASE FORMULATION; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ARRHYTHMIA; HUMANS; HYPERTENSION; INSULIN-LIKE GROWTH FACTOR I; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; SLEEP APNEA SYNDROMES; SOMATOSTATIN;

EID: 0037340306     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020072     Document Type: Review

References (67)

1. Melmed S 1998 Tight control of growth hormone: an attainable outcome for acromegaly treatment. J Clin Endocrinol Metab 83:3409-3410
2. Klibanski A, Ho K, Freda PU, Clemmons DR, Barkan AL, Kleinberg DL, Trainer P, Swearingen B, Molitch ME, Wass JAH, Thorner MO, Melmed S, Strasburger CJ, Frohman LA 2001 State-of the art strategies for the diagnosis and management of acromegaly. The Endocrinologist 11:223-232
3. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 83:2730-2734
4. Muravchick S 2000 Preoperative assessment of the elderly patient. Anesthesiol Clin North America 18:71-89
5. Belzberg H, Rivkind Ai 1999 Preoperative cardiac preparation. Chest 115(5 Suppl):82S-95S
6. Bach DS 1998 Management of specific medical conditions in the perioperative period. Prog Cardiovasc Dis 40:469-476
7. Peters A, Kerner W 1995 Perioperative management of the diabetic patient. Exp Clin Endocrinol Diabetes 103:213-218
8. Drain CB 1996 Physiology of respiratory system related to anesthesia. CRNA 7:163-180
9. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Glossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance, ML, von Werder K, Wass J, Giustina A 2002 Consensus: guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
10. Kreutzer J, Vance ML, Lopes MBS, Laws Jr ER 2001 Surgical management of GH-secreting pituitary adenoma: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072-4077
11. Freda PU, Wardlaw SL 1998 Primary medical therapy for acromegaly. J Clin Endocrinol Metab 83:3031-3033
12. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G 2000 Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 85:4099-4103
13. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786
14. Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
15. Freda PU, Wardlaw SL, Post KD 1998 Long-term endocrinologic follow-up after transsphenoidal surgery for acromegaly. J Neurosurg 89:353-358
16. Seidman PA, Kofke WA, Policare R, Young M 2000 Anesthetic complications in acromegaly. Br J Anaesth 84:179-182
17. Saccà L, Cittadini A, Fazio S 1994 Growth hormone and the heart. Endocr Rev 15:555-573
18. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
19. Fazio S, Cittadini A, Biondi B, Palmieri EA, Riccio G, Boné F, Oliviero U, Saccà L 2000 Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab 85:179-182
20. Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Vujisic B, Petrovic M, Nikolic-Djurovic M, Simic M, Pekic S, Marinkovic J 2002 High output heart failure in patients with newly diagnosed acromegaly. Am J Med 112:610-616
21. Vianna CB, Vieira ML, Mady C, Lieberman B, Durazzo AE, Knoepfelmacher M, Salgado LR, Ramires JA 2002 Treatment of acromegaly improves myocardial abnormalities. Am Heart J 143:873-876
22. Fazio S, Cittadini A, Sabatini D, Merola B, Colao AM, Biondi B, Lombardi G, Saccà L 1993 Evidence for biventricular involvement in acromegaly: a Doppler echocardiography study. Eur Heart J 14:26-33
23. Bruch C, Herrmann B, Schmermund A, Bartel T, Mann K, Erbel R 2002 Impact of disease activity on left ventricular performance in patients with acromegaly. Am Heart J 144:538-543
24. Hradec J, Marek J, Kral J, Janota T, Poloniecki J, Malic M 1993 Long-term echocardiographic follow-up of acrornegalic heart disease. Am J Cardiol 72:205-210
25. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G 1999 Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84:17-23
26. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Call A, de Divitiis E, Lombardi G 1997 Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314
27. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boeriln V, Lancranjan I, Lombardi G 2000 Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85:3132-3140
28. Lira MJ, Barkan AL, Buda AJ 1992 Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 117:719-726
29. Hradec J, Kral J, Janota T, Krsek M, Hana V, Marek J, Malik N 1999 Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 83:1506-1509
30. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Petretta M, Salvatore M, Lombardi G 2001 Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor 1 levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557
31. Giustina A, Boni E, Romanelli G, Grassi V, Giustina G 1995 Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75:1042-1047
32. Manelli F, Desenzani P, Boni E, Bugari G, Negrini F, Romanelli G, Grassi G, Giustina A 1999 Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 2:205-210
33. Herrmann BL, Bruch C, Saller B, Ferdin S, Dagres N, Ose C, Erbel R, Mann K 2001 Occurrence of ventricular late potentials in patients with active acromegaly. Clin Endocrinol (Oxf) 55:201-207
34. Suyama K, Uchida D, Tanaka T, Saito J, Noguchi Y, Nakamura S, Tatsuno I, Saito Y, Saeki N 2000 Octreotide improved ventricular arrhythmia in an acromegalic patient. Endocr J 47(Suppl):S73-S75
35. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Petretta M, Salvatore M, Lombardi G 1999 Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab 84:1518-1523
36. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, Ross JL, Raps E, Ozer MN, Brass LM, Malone ME, Goldberg S, Booss J, Hanley DF, Toole JF, Greengold NL, Rhew DC 1999 Prevention of first stroke: a review of guidelines and a multidisciplinary consensus statement from National Stroke Association. JAMA 281:1112-1120
37. Ben-Shlomo A, Melmed S 2001 Acromegaly. Endocrinol Metab Clin North Am 30:565-583
38. Schmitt H, Buchielder M, Radespiel-Tröger M, Fahlbusch R 2000 Difficult intubation in acromegaly patients. Incidence and predictability. Anesthesiology 93:110-114
39. Williams RG, Richards SH, Mills RG, Eccles R 1994 Voice changes in acromegaly. Laryngoscope 104:484-487
40. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, Melmed S 1992 Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117:711-718
41. Garcia-Rio F, Pino JM, Diez JJ, Ruiz A, Villasante C, Villamor J 2001 Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion. Am J Respir Crit Care Med 164:852-857
42. Rosenow F, Reuter S, Deuss U, Szelies B, Hilgers RD, Winkelmann W, Heiss WD 1996 Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin Endocrinol (Oxf) 45:563-569
43. Hart TB, Radow SK, Blackard WG, Tucker HS, Cooper KR 1985 Sleep apnea in active acromegaly. Arch Intern Med 145:865-866
44. Ip MSM, Tan KCB, Peh WCG, Lain KSL 2001 Effect of sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 55:477-483
45. Grunstein RR, Ho KKY, Sullivan CE 1994 Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 121:478-483
46. Grunstein RR, Ho KY, Sullivan CE 1991 Sleep apnea in acromegaly. Ann Intern Med 115:527-532
47. Cadieux R, Kales A, Santen R, Bixler E, Godon R 1982 Endoscopic findings in sleep apnoea associated with acromegaly. J Clin Endocrinol Metab 55:18-22
48. Isono S, Saeki N, Tanaka A, Nishino T 1999 Collapsibility of passive pharynx in patients with acromegaly. Am J Respir Crit Care Med 160:64-68
49. He J, Kryger MH, Zorich FJ, Conway W, Roth T 1988 Mortality and apnea index in obstructive sleep apnea. Experience in 385 male patients. Chest 94:9-14
50. Koskenvup M, Kaprio J, Partinen M, Langinvainio H, Sama S, Heikkila K 1985 Snoring as a risk factor for hypertension and angina pectoris. Lancet 1:893-896
51. Hung J, Whitford EG, Parsons RW, Hillman DR 1990 Association of sleep apnoea with myocardial infarction in men. Lancet 336:261-264
52. Mohsenin V 2001 Sleep-related breathing disorders and risk of stroke. Stroke 32:1271-1278
53. Chanson P, Timsit J, Benoit O, Augendre B, Moulonguet M, Guillausseau PJ, Warnet A, Lubetzki J 1986 Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995. Lancet 1:1270-1271
54. Leibowitz G, Shapiro MS, Salameh M, Glaser B 1994 Improvement of sleep apnoea due to acromegaly during short-term treatment with octreotide. J Intern Med 236:231-235
55. Young ML, Hanson CW 1993 An alternative to tracheostomy following transsphenoidal hypophysectomy in a patient with acromegaly and sleep apnea. Anesth Analg 76:446-449
56. Koop BL, Harris AG, Ezzat S 1994 Effects of octreotide on glucose tolerance in acromegaly. Eur J Endoerinol 130:581-586
57. Hoogwerf BJ 2001 postoperative management of the diabetic patient. Med Clin North Am 85:1213-1228
58. Barkan A, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ 1988 Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040-1048
59. Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ 1994 Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79:1416-1423
60. Lucas-Morante T, García-Uría J, Estrada J, Saucedo G, Cabello A, Alcaňiz J, Barceló B 1994 Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81:10-14
61. Stevenaert A, Beckers A 1996 Presurgical octreotide: treatment in acromegaly. Metabolism 45(Suppl 1):72-74
62. Newman CE, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Steeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL 1998 Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040
63. Tamura M, Yokoyama N, Abe Y, Sera N, Tominaga T, Ashizawa K, Ejima E, Kiriyama T, Uetani M, Kuwayama A, Nagataki S 1998 Preoperative treatment of growth hormone-producing pituitary adenoma with continuous subcutaneous infusion of octreotide. Endocr J 45:269-275
64. Tachibana E, Saito K, Yoshida J 1999 Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas. Neurol Med Clair (Tokyo) 39:496-499
65. Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J 1999 Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141:399-405
66. Abe T, Lüdecke DK 2001 Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical center. Eur J Endocrinol 145:137-145
67. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Glustina A, Carella C 2002 Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65-71